Akero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic liver diseases such as MASH (nonalcoholic steatohepatitis).
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 49 | New buy | 4,256 | $202,075 | 0.0% |
| GENERAL ATLANTIC, L.P. (auto-surfaced) | — | Holds (flat) | 5,733,989 | $272,249,798 | 8.2% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.